New twist on antibiotic hunt hits pay dirt

The antibiotic discovery pipeline received a much-needed boost in January. Teixobactin, a natural product from previously uncultured bacteria, was shown to have potent activity against Gram-positive pathogens and a novel mechanism of action, making it a potentially valuable asset in the battle against bacterial resistance. Perhaps more importantly, this discovery validated a platform that provides researchers with a new way to tap into the secondary metabolites of the so-called microbial dark matter — the 99% of bacteria that won’t grow under standard laboratory conditions.

[Read more at Nature Reviews Drug Discovery (paywall) or download PDF // February 13, 2015 ]